Multidose Psilocybin for OCD: Johns Hopkins Open-Label Trial Insights

Johns Hopkins Trial Finds Multidose Psilocybin May Reduce OCD Symptoms

In a recently published open-label, waitlist-controlled clinical trial at Johns Hopkins University School of Medicine, researchers found that two successive doses of psilocybin, administered over two weeks, were well-tolerated and led to significant reductions in obsessive-compulsive disorder (OCD) symptoms among adults who had not responded to standard treatments. The study, registered as NCT05546658, enrolled 37 participants with moderate to severe OCD, of whom 30 completed the one-month follow-up. The immediate-treatment group (N=16) experienced greater reductions in Yale-Brown Obsessive Compulsive Scale (Y-BOCS) scores compared to the waitlist-control group (N=14), with effects persisting one month after the second dose for both groups. This is among the first controlled studies to assess repeated psilocybin dosing for OCD, a condition affecting 2% of the global population and often resistant to existing therapies.

Mechanism, Subjective Effects, and Clinical Context

Psilocybin, a classic serotonergic psychedelic, is hypothesized to modulate brain networks implicated in OCD, potentially disrupting maladaptive thought patterns and enhancing cognitive flexibility. In this trial, reductions in OCD symptoms were correlated with acute subjective effects measured by the Mystical Experience Questionnaire (MEQ), Challenging Experience Questionnaire (CEQ), and the 11-Dimensional Altered States of Consciousness (11D-ASC) scale. Participants also reported improvements in anxiety, depression, and quality of life, as measured by the State-Trait Anxiety Inventory (STAI), Beck Depression Inventory-II (BDI-II), and Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q). Notably, the study's open-label design and use of a waitlist control, rather than placebo, reflect both ethical considerations and the challenge of blinding psychedelic interventions, but limit the ability to fully separate drug effects from expectancy or support factors.

Policy, Regulatory, and Research Implications

The positive safety and efficacy signals from this trial support the rationale for larger, randomized, double-blind, placebo-controlled studies of psilocybin for OCD. With only about half of OCD patients responding to conventional pharmacotherapy or psychotherapy, there is a critical need for new interventions. The U.S. Food and Drug Administration (FDA) has already granted Breakthrough Therapy designation to psilocybin for major depressive disorder, and these new findings could inform future regulatory pathways for OCD-specific indications. The trial's multidose protocol is particularly noteworthy, as most prior psychedelic studies have relied on single-dose models. This approach may be more relevant for chronic, relapsing conditions like OCD, but also raises questions about cumulative effects, optimal dosing intervals, and long-term safety. Importantly, the study's design—using a waitlist rather than an inactive placebo—may set a precedent for ethically navigating trials in populations with severe, treatment-resistant illness, but could complicate regulatory review if not paired with blinded, controlled data in future pivotal studies.

Risks, Limitations, and Unknowns

While the trial found repeated psilocybin dosing to be well-tolerated, with no serious adverse events reported, several limitations warrant caution. The open-label design introduces potential bias, and the small sample size (N=37, with 30 completing follow-up) limits generalizability. The absence of a true placebo control means expectancy effects cannot be fully excluded. Furthermore, the durability of symptom reduction beyond one month remains unknown, as does the safety of repeated dosing over longer periods. The study also found that acute subjective experiences—such as mystical-type or challenging experiences—correlated with clinical improvement, but it is unclear whether these are necessary for therapeutic benefit or simply markers of drug intensity. A non-obvious risk surfaced in this trial: a subset of participants with high baseline anxiety experienced transient increases in distress during dosing sessions, underscoring the need for careful screening and robust psychological support in future studies. This highlights a critical decision point for trial designers: balancing the potential for rapid symptom relief with the risk of acute psychological discomfort, especially in vulnerable populations.

Outlook: Next Steps for Psilocybin and OCD Research

The Johns Hopkins trial provides early, promising evidence that multidose psilocybin may offer a new avenue for patients with treatment-resistant OCD, but definitive conclusions await larger, blinded studies with longer follow-up. The trial's design and findings are likely to influence both research methodology and regulatory expectations for psychedelic therapeutics targeting OCD. As the field moves forward, key questions include optimal dosing strategies, mechanisms of action, and the role of subjective experience in mediating clinical outcomes. For now, psilocybin remains an investigational therapy for OCD, but this study marks a meaningful step toward addressing a major unmet need in mental health care.

Reviewed by Dr. Alex Monroe, MD, PhD (Neuropsychiatry), on 2026-10-07. Research for this article included direct review of the trial registry, primary publication, and FDA regulatory guidance.